Genomic DNA was extracted from the peripheral blood collected at week 0 (Macherey-Nagel kit, NucleoSpin Blood XL, Düren, Germany; or with standard method).
Two hundred and eighty-two PHSS patients were genotyped using the
Illumina Human1M-Duo array (Illumina Inc, San Diego, California, USA) within HYPERGENES project [19 (
link)] and 119 using the Illumina HumanOmniExpress array within InterOmics project (
http://www.interomics.eu/).
Two hundred and fifteen HCTZ-Milan samples were genotyped using the
Illumina Human1M-Duo array within HYPERGENES project [19 (
link)].
The imputation was performed using Minimac [20 (
link)] and 1000 Genomes haplotypes as reference (release March 2012). Imputed single-nucleotide polymorphisms (SNPs) with low imputation quality (Rsq < 0.8) were not used in the association analysis. Genotyping and imputation details are in
Methods S5 (
Supplemental Digital Content,
http://links.lww.com/HJH/A467).
Chittani M., Zaninello R., Lanzani C., Frau F., Ortu M.F., Salvi E., Fresu G., Citterio L., Braga D., Piras D.A., Carpini S.D., Velayutham D., Simonini M., Argiolas G., Pozzoli S., Troffa C., Glorioso V., Kontula K.K., Hiltunen T.P., Donner K.M., Turner S.T., Boerwinkle E., Chapman A.B., Padmanabhan S., Dominiczak A.F., Melander O., Johnson J.A., Cooper-Dehoff R.M., Gong Y., Rivera N.V., Condorelli G., Trimarco B., Manunta P., Cusi D., Glorioso N, & Barlassina C. (2015). TET2 and CSMD1genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. Journal of hypertension, 33(6), 1301-1309.